For Novartis, 2012 Is Set To Be A Bumpy Ride
This article was originally published in The Pink Sheet Daily
Executive Summary
With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.